Artiva COO sells shares to cover tax withholding

Artiva Biotherapeutics COO Jennifer Bush reported an automatic sale of 8,790 common shares to cover tax withholding on vested restricted stock units.

Rhea-AI Filing Summary

Artiva Biotherapeutics COO Jennifer Bush reported an automatic sale of 8,790 common shares to cover tax withholding on vested restricted stock units. The shares were sold in the open market at a weighted average price of $9.0078 per share, within a range of $8.7439 to $9.0104. After this sell-to-cover transaction under the company’s tax policy, she continues to hold 337,920 shares directly.

Insider Trade Summary

Net Seller: 8,790 shares

Net Sell 1 txn

Insider Bush Jennifer

Role COO, CLO, Compliance Officer

Sold 8,790 shs ($79K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,790	$9.0078	$79K

Holdings After Transaction: Common Stock — 337,920 shares (Direct)

Footnotes (2)

1. F1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7439 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 8,790 shares Weighted average sale price: $9.0078 per share Price range: $8.7439–$9.0104 per share +2 more

5 metrics

Shares sold 8,790 shares Open-market sale on 2026-05-19 to cover tax withholding

Weighted average sale price $9.0078 per share Sell-to-cover transaction on 2026-05-19

Price range $8.7439–$9.0104 per share Range of prices for the reported sale

Shares held after transaction 337,920 shares Direct ownership following the 8,790-share sale

Net shares sold 8,790 shares Net-sell direction per transaction summary

Key Terms

sell-to-cover policy, restricted stock units, weighted average sale price

3 terms

sell-to-cover policy financial

"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person."

restricted stock units financial

"to cover tax withholding obligations in connection with the vesting and release of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7439 and $9.0104."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Artiva Biotherapeutics (ARTV) report for Jennifer Bush?

Artiva Biotherapeutics reported that COO Jennifer Bush sold 8,790 common shares. The sale was an automatic sell-to-cover transaction to satisfy tax withholding on vesting restricted stock units, rather than a discretionary open-market sale for investment purposes.

At what price did Jennifer Bush’s Artiva (ARTV) shares sell in this Form 4 filing?

The shares sold at a weighted average price of $9.0078 per share. Individual trade prices ranged between $8.7439 and $9.0104, and the company will provide detailed price breakdowns to regulators or shareholders upon request if more granular information is needed.

Why did Artiva’s COO sell 8,790 shares according to the Form 4?

The sale was made to cover tax withholding obligations tied to restricted stock units that vested. Under Artiva’s sell-to-cover policy, enough shares are automatically sold to satisfy taxes, so the timing and size are driven by tax needs rather than market views.

How many Artiva (ARTV) shares does Jennifer Bush hold after this transaction?

Following the sell-to-cover transaction, Jennifer Bush directly holds 337,920 Artiva common shares. This remaining stake shows the reported sale represents a relatively small portion of her overall holdings and primarily serves to address tax obligations from equity compensation.

Was Jennifer Bush’s Artiva share sale discretionary or automatic?

The filing states the share sale was automatic under Artiva’s sell-to-cover policy. It occurred solely to meet tax withholding requirements on restricted stock unit vesting, and the Form 4 notes it was not executed at Jennifer Bush’s discretion or as a strategic portfolio decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 09:51 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bush Jennifer

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO, CLO, Compliance Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		S		8,790(1)	D	$9.0078(2)	337,920	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7439 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Andrew Cronauer, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)